Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Moutinho, Catia|||0000-0003-3885-0847
  • Moran, S.|||0000-0003-4192-8983
  • Heyn, Holger|||0000-0002-3276-1889
  • Sebio, Ana|||0000-0003-3333-2370
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Pommier, Yves
  • Esteller, M.|||0000-0003-4490-6093
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

  • Morancho, Beatriz|||0000-0003-3369-8647
  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Esgueva, Antonio|||0000-0002-8622-064X
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Cosimo, Serena Di
  • Prat, Aleix|||0000-0003-2377-540X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Rubio, Isabel T.|||0000-0003-0035-0679
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not known. This study evaluates the efficacy of anti-IL-6 therapies using breast cancer patient derived xenografts (PDXs). During the generation of our collection of PDXs, we showed that the successful engraftment of tumor tissue in immunodeficient mice correlates with bad prognosis. Four PDXs out of six were resistant to anti-IL-6 therapies and the expression of IL-6, its receptor or the levels of phospho-STAT3 (the active form of the signal transducer) did not correlate with sensitivity. Using cell cultures established from the PDXs as well as samples from in vivo treatments, we showed that only tumors in which the activation of STAT3 depends on IL-6 respond to the blocking antibodies. Our results indicate that only a fraction of breast tumors are responsive to anti-IL-6 therapies. In order to identify responsive tumors, a functional assay to determine the dependence of STAT3 activation on IL-6 should be performed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

  • Almazán-Moga, Anna
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Vidal, Isaac
  • Molist, Carla|||0000-0003-3251-0083
  • Giralt, Irina|||0000-0002-9094-4325
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Soriano, Aroa|||0000-0001-9659-1471
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Alfranca, Arantzazu|||0000-0002-3732-5816
  • Garcia-Castro, Javier|||0000-0001-7604-1640
  • Sánchez de Toledo, Joan|||0000-0002-9108-4750
  • Roma, Josep|||0000-0001-7692-6123
  • Gallego, Soledad|||0000-0002-4712-9624
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation. This strategy allowed us to demonstrate the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic) impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and metastases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

  • Chaib, Imane
  • Karachaliou, Niki
  • Pilotto, Sara
  • Codony-Servat, Jordi
  • Cai, Xueting
  • Li, Xuefei
  • Drozdowskyj, Ana
  • Codony Servat, Carles|||0000-0001-8928-2312
  • Yang, Jie
  • Hu, Chunping
  • Cardona Zorrilla, Andrés Felipe|||0000-0003-3525-4126
  • Lopez Vivanco, Guillermo
  • Vergnenegre, Alain
  • Sánchez Torres, José Miguel
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Marinis, Filippo de
  • Passaro, Antonio|||0000-0002-7575-3870
  • Carcereny, Enric|||0000-0001-5235-5602
  • Reguart, Noemi|||0000-0001-8190-499X
  • Garcia Campelo, Charo
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Sperduti, Isabella
  • Rodriguez, Sonia
  • Lavazzi, Chiara
  • Verlicchi, Alberto
  • Aguirre, Itziar de
  • Queralt, C.|||0000-0001-9875-0173
  • Wei, Jia|||0000-0001-9621-529X
  • Estrada-Tejedor, Roger|||0000-0002-2983-0492
  • Puig de la Bellacasa, Raimon|||0000-0001-8349-4082
  • Ramirez, Jose Luis
  • Jacobson, Kirstine
  • Ditzel, Henrik J.
  • Santarpia, Mariacarmela
  • Viteri, Santiago|||0000-0002-7572-1123
  • Molina, Miguel Angel
  • Zhou, Caicun
  • Cao, Peng
  • Ma, Patrick C.
  • Bivona, Trever
  • Rosell, Rafael|||0000-0003-0817-3400
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals.We hypothesized that both signal transducer and activator of transcription 3 (STAT3) and Src-YES-associated protein 1 (YAP1) signaling are dually activated during EGFR TKI treatment to limit therapeutic response. Methods: We used MTT and clonogenic assays, immunoblotting, and quantitative polymerase chain reaction to evaluate the efficacy of EGFR TKI alone and in combination with STAT3 and Src inhibition in three EGFR-mutant NSCLC cell lines. The Chou-Talalay method was used for the quantitative determination of drug interaction. We examined tumor growth inhibition in one EGFR-mutant NSCLC xenograft model (n¼4 mice per group). STAT3 and YAP1 expression was evaluated in tumors from 119 EGFR-mutant NSCLC patients (64 in an initial cohort and 55 in a validation cohort) by quantitative polymerase chain reaction. Kaplan-Meier and Cox regression analyses were used to assess the correlation between survival and gene expression. All statistical tests were two-sided. Results: We discovered that lung cancer cells survive initial EGFR inhibitor treatment through activation of not only STAT3 but also Src-YAP1 signaling. Cotargeting EGFR, STAT3, and Src was synergistic in two EGFR-mutant NSCLC cell lines with a combination index of 0.59 (95% confidence interval [CI] ¼ 0.54 to 0.63) for the PC-9 and 0.59 (95% CI¼0.54 to 0.63) for the H1975 cell line. High expression of STAT3 or YAP1 predicted worse progression-free survival (hazard ratio [HR] ¼ 3.02, 95% CI¼1.54 to 5.93, P ¼ .001, and HR¼2.57, 95% CI¼1.30 to 5.09, P ¼ .007, respectively) in an initial cohort of 64 EGFR-mutant NSCLC patients treated with firstline EGFR TKIs. Similar results were observed in a validation cohort. Conclusions: Our study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma, the oncogenic role of the ligands

  • Almazán-Moga, Anna
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Molist, Carla|||0000-0003-3251-0083
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Pyczek, Joanna
  • Simon-Keller, Katja|||0000-0003-2340-8765
  • Giralt, Irina|||0000-0002-9094-4325
  • Vidal, Isaac
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Soriano, Aroa|||0000-0001-9659-1471
  • Navarro, Susanna|||0000-0001-8160-9536
  • Tirado, Òscar Martínez
  • Ferreres Piñas, Joan Carles|||0000-0001-7742-0239
  • Santamaria, Anna
  • Rota, Rossella
  • Hahn, Heidi
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Gallego, Soledad|||0000-0002-4712-9624
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. The expression of HH ligands was studied by qPCR, western blot and immunohistochemistry. Functional and animal model studies were carried out with cells transduced with shRNAs against HH ligands or treated with HH-specific inhibitors (Vismodegib and MEDI-5304). Finally, the molecular characterisation of an off-target effect of Vismodegib was also made. The results showed a prominent expression of HH ligands supporting an autocrine ligand-dependent activation of the pathway. A comparison of pharmacologic Smoothened inhibition (Vismodegib) and HH ligand blocking (MEDI-5304) is also provided. Interestingly, a first description of pernicious off-target effect of Vismodegib is also reported. The clarification of the HH pathway activation mechanism in RMS opens a door for targeted therapies against HH ligands as a possible alternative in the future development of better treatment protocols. Moreover, the description of a pernicious off-target effect of Vismodegib, via unfolded protein response activation, may mechanistically explain its previously reported inefficiency in several ligand-dependent cancers.